Author(s)

Eduardo Santiesteban, Leslie Perez, Sailyn Alfonso, Elia Neninger, Soraida Acosta, Yoana Flores, Maurenis Hernandez, Carmen Viada, Robin García, Meylán Cepeda, Daymys Estevez, Yoisbel Moreno, Amparo Macías

Celestino Hernández Robau Hospital, Villa Clara, Cuba.
Center of Molecular Immunology, Havana, Cuba.
Hermanos Ameijeiras Hospital, Havana, Cuba.
José Ramón López Tabranes Hospital, Matanzas, Cuba.
National Institute of Oncology and Radiobiology, Havana, Cuba.
Saturnino Lora Hospital, Santiago de Cuba, Cuba.

Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The aim of this study was to evaluate safety and efficacy of racotumomab-alum in advanced NSCLC patients with progressive disease. This expanded access program included 86 histologically confirmed NSCLC patients, 18 years or older age, with advanced disease and without therapeutic option, with ECOG performance status ≤3, adequate organ functions and signed informed consent. The primary endpoint was overall survival and toxicity was measure assessed treatment-related toxicity according CTCAEv3. The study was approved by ethical review boards of participant institutions. Racotumomab-alum treatment consisted in 5 biweekly intradermal doses (1 mg/mL) during the induction phase of treatment (2 months). The maintenance phase consisted in monthly re-immunizations until unacceptable toxicity or PS worsening. The median overall survival time of all patients treated with racotumomab-alum was 8.96 months. The survival rates at 12 and 24 months were 42.8% and 28.0%, respectively. Patients that completed the induction phase of treatment (five doses or more) reached a median OS of 12.1 months. The most common adverse events were injection site reaction, bone pain, cough and asthenia. Racotumomab-alum cancer vaccine could be considered an effective and safe treatment option as second-line therapy for advanced NSCLC. Further clinical studies should be conducted to confirm this result.

Non-Small Cell Lung Cancer, Cancer Vaccine, Second-Line Treatment

Santiesteban, E. , Perez, L. , Alfonso, S. , Neninger, E. , Acosta, S. , Flores, Y. , Hernandez, M. , Viada, C. , García, R. , Cepeda, M. , Estevez, D. , Moreno, Y. and Macías, A. (2014) Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer. International Journal of Clinical Medicine, 5, 844-850. doi: 10.4236/ijcm.2014.514113.